Novartis, INC.
Multinational biopharmaceutical company
Based in DC
🤖
AI Overview
With $1.4M in lobbying spend across 29 quarterly filings, Novartis, INC. is a significant lobbying presence. They deploy 12 individual lobbyists
$1.4M
Total Lobbying Spend
29
Quarterly Filings
1
Lobbying Firms Used
12
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2019 | $150K |
| 2020 | $200K |
| 2021 | $200K |
| 2022 | $350K |
| 2023 | $200K |
| 2024 | $200K |
| 2025 | $150K |
Lobbying Firms
FORBES-TATE
What They Lobby For
- Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), FY 2020 appropriations.
- Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
- Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies.
- Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
- Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
- Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings.
- Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to H.R. 925 - The Heroes Act.
- Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
- Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
- Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Related Investigations
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.